Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by sah1on May 12, 2017 1:20pm

192 Views

Post# 26237987

RE:RE:RE:RE:Clarification from Fred.....

Yes, I get this completely. I remember for Pg congenital, PLI put a value of $500/l of plasma and for Pg use in diabetic ulcers a value of $5000 value/l of plasma was mentioned because only micrograms of Pg are needed in the latter treatment.

Thanks, Eric:-)

Bullboard Posts

Debt-free cannabis company set for next stage of growth